| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | M Shawkat Razzaque | |
| P2860 | cites work | Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 |
| Cellular signaling by fibroblast growth factor receptors | Q24301087 | ||
| Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs | Q24305543 | ||
| A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium | Q24308202 | ||
| Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein | Q24309454 | ||
| Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro | Q24314927 | ||
| FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 | ||
| Mutation of the mouse klotho gene leads to a syndrome resembling ageing | Q24328782 | ||
| Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 | ||
| Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members | Q24683254 | ||
| Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain | Q28141252 | ||
| Role of fibroblast growth factor 23 in health and in chronic kidney disease | Q28254210 | ||
| Fibroblast growth factor 23: roles in health and disease | Q28262842 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis | Q28289695 | ||
| Genetic evidence of serum phosphate-independent functions of FGF-23 on bone | Q28473286 | ||
| Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo | Q28572995 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism | Q29620323 | ||
| Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation | Q33938586 | ||
| Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers | Q33974129 | ||
| Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23 | Q34075026 | ||
| FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting | Q34227442 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| Proximal tubular handling of phosphate: A molecular perspective | Q34563763 | ||
| Cellular and molecular events leading to renal tubulointerstitial fibrosis. | Q34786418 | ||
| Evolution of the Fgf and Fgfr gene families | Q35913683 | ||
| A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis | Q35925637 | ||
| Structural basis for fibroblast growth factor receptor activation | Q36111391 | ||
| Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter | Q36191092 | ||
| Hypophosphatemia: an update on its etiology and treatment | Q36272304 | ||
| Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17 | Q36288869 | ||
| Premature aging in klotho mutant mice: cause or consequence? | Q36757962 | ||
| The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis | Q36860289 | ||
| Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system | Q36891815 | ||
| Does renal ageing affect survival? | Q36896257 | ||
| New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. | Q36905432 | ||
| Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? | Q36966608 | ||
| FGFR3 and FGFR4 do not mediate renal effects of FGF23. | Q36985772 | ||
| alpha-Klotho: a regulator that integrates calcium homeostasis | Q37045462 | ||
| In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis | Q37072412 | ||
| Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? | Q37182735 | ||
| Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23 | Q37418420 | ||
| Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. | Q40447584 | ||
| An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. | Q40482177 | ||
| Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders | Q40530218 | ||
| Klotho and Na+,K+-ATPase activity: solving the calcium metabolism dilemma? | Q41900414 | ||
| Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. | Q42493065 | ||
| Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process | Q42736434 | ||
| Klotho protein promotes adipocyte differentiation | Q42801686 | ||
| Does FGF23 toxicity influence the outcome of chronic kidney disease? | Q43078080 | ||
| Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia | Q44414604 | ||
| Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. | Q44465622 | ||
| Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders | Q45187805 | ||
| Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. | Q45197408 | ||
| Is vitamin D indispensable for Ca2+ homeostasis: lessons from knockout mouse models? | Q46381158 | ||
| Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. | Q46680438 | ||
| Pathogenic role of Fgf23 in Hyp mice. | Q46921328 | ||
| Severely reduced production of klotho in human chronic renal failure kidney | Q49064415 | ||
| The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. | Q52572405 | ||
| Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. | Q53964449 | ||
| FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. | Q54733425 | ||
| DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. | Q54943458 | ||
| Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice | Q56767950 | ||
| Role of vitamin D metabolites in phosphate transport of rat intestine | Q69816011 | ||
| Effects of vitamin D on phosphate transport and incorporation into mucosal constituents of rat intestinal mucosa | Q72359663 | ||
| The collagen-specific molecular chaperone HSP47: is there a role in fibrosis? | Q79433884 | ||
| FGF-23, vitamin D and calcification: the unholy triad | Q80394650 | ||
| Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism | Q81853118 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | F470-6 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | American Journal of Physiology - Renal Physiology | Q2610177 |
| P1476 | title | FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? | |
| P478 | volume | 296 |
| Q33832689 | A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. |
| Q36492520 | Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function |
| Q37244863 | Can features of phosphate toxicity appear in normophosphatemia? |
| Q37498019 | Can salivary phosphate levels be an early biomarker to monitor the evolvement of obesity? |
| Q37365630 | Decline in muscle strength and running endurance in klotho deficient C57BL/6 mice |
| Q35003219 | Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions |
| Q34072221 | Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging |
| Q37507342 | Disorders of phosphate homeostasis and tissue mineralisation |
| Q28085476 | Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity |
| Q43040796 | Dysregulation of renal vitamin D metabolism in the uremic rat. |
| Q34755816 | Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease |
| Q36922455 | Emerging role of circulating calcifying cells in the bone-vascular axis |
| Q35073296 | Evaluation of hypophosphatemia: lessons from patients with genetic disorders. |
| Q42878661 | FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism |
| Q43074642 | FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. |
| Q35203191 | Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification |
| Q90376213 | Fibroblast growth factor 23 and symmetric dimethylarginine concentrations in geriatric cats |
| Q37832285 | Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications |
| Q24604832 | Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes |
| Q54534133 | Fibroblast growth factor-23 abolishes 1,25-dihydroxyvitamin D₃-enhanced duodenal calcium transport in male mice. |
| Q36992835 | Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice |
| Q33717722 | Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells |
| Q34985917 | Heat shock protein 47: a novel biomarker of phenotypically altered collagen-producing cells |
| Q89161363 | Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature |
| Q92669192 | Identification of a p.Trp403* nonsense variant in PHEX causing X-linked hypophosphatemia by inhibiting p38 MAPK signaling |
| Q33755187 | Identifying aging-related genes in mouse hippocampus using gateway nodes |
| Q33572351 | In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels |
| Q37415834 | Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model |
| Q28535055 | Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate |
| Q36864419 | Klotho, FGF21 and FGF23: Novel Pathways to Musculoskeletal Health? |
| Q34119083 | Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks |
| Q57168590 | Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis |
| Q60921741 | Magnesium: Are We Consuming Enough? |
| Q35059924 | Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system |
| Q41775580 | Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q35025454 | Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism? |
| Q51323466 | Phosphate toxicity: a stealth biochemical stress factor? |
| Q35059905 | Phosphate toxicity: new insights into an old problem |
| Q43109214 | Rapamycin-induced phosphaturia |
| Q45681091 | Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial |
| Q35126790 | Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase |
| Q24625902 | The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis |
| Q36318290 | The consequences of chronic kidney disease on bone metabolism and growth in children |
| Q35059753 | The dualistic role of vitamin D in vascular calcifications |
| Q38896674 | The putative role of the antiageing protein klotho in cardiovascular and renal disease |
| Q36992839 | The role of Klotho in energy metabolism |
| Q42529430 | Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372 |
| Q33579283 | Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature |
| Q55496554 | Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. |
| Q38633152 | Vitamin D, phosphate, and vasculotoxicity. |
| Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.